H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on GOSS stock, giving a Buy rating on March 14.
Patrick Trucchio has given his Buy rating due to a combination of factors including the promising potential of Gossamer Bio’s lead asset, seralutinib. This inhaled tyrosine kinase inhibitor is set to transform the treatment approach for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib’s unique mechanism of targeting vascular remodeling, rather than just providing vasodilation, positions it as a potential best-in-class therapy. The ongoing Phase 3 trial, PROSERA, is anticipated to deliver pivotal data by the fourth quarter of 2025, which could significantly enhance its market position.
Additionally, Gossamer Bio’s strategic expansion into PH-ILD presents a substantial growth opportunity, with a Phase 3 program expected to commence in the second half of 2025. The inhaled delivery method of seralutinib aims to maximize pulmonary bioavailability while minimizing systemic exposure, potentially offering a safer alternative to existing systemic treatments. With top-line data for PAH expected within a year and a clear development path for PH-ILD, Trucchio sees a compelling risk-reward scenario at current stock levels, reinforcing his confidence in seralutinib’s ability to drive long-term value.
In another report released on March 14, Leerink Partners also maintained a Buy rating on the stock with a $6.00 price target.